EpCAM+ CTCs have previously been detected in 28−35% of advanced HCC patients in Western cohorts by CellSearch [5, 6,11], which is lower than the frequencies reported in Asian cohorts (EpCAM+ CTCs: 44−74%) focusing mostly on resectable HCC patients [8,10,12]. Here, EPCAM is linked to hepatocellular carcinoma.